The Innovative Medicines Initiative: A Public Private Partnership Model to Foster Drug Discovery

Abstract

The Innovative Medicines Initiative (IMI) is a large-scale public–private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI aims to boost the development of new medicines across Europe by implementing new collaborative endeavours between large pharmaceutical companies and other key actors in the health-care ecosystem, i.e., academic institutions, small and medium enterprises, patients, and regulatory authorities. Currently there are more than 40 IMI projects covering the whole value chain of pharmaceutical R&D, but with a strong focus on drug discovery, as an ideal arena where the PPP concept of pre-competitive collaboration can rapidly deliver results. This article review recent achievements of the IMI consortia of relevance to drug discovery, providing proof-of-concept evidence for the efficiency of this new model of collaboration.

Public-private Partnerships in Biomedical Research and Health Innovation for Alzheimer's Disease and other Dementias

“…Public-private partnerships are alliances in which public and private entities work together and share resources and results to achieve mutually agreed objectives, which would have been out of range for each individual partner. Public-private partnerships are the most prominent example of multistakeholder collaborations that bring together the critical means from academia, governments, authorities, the pharmaceutical industry and patient organisations to drive the process of health innovation (Goldman, Compton and Mittleman, 2013;Vaudano, 2013). Their ultimate goal is to produce the maximum possible value, greater than the sum of what each partner alone could accomplish without collaboration.…”

“…The pharmaceutical industry has been facing challenges of low drug development productivity, dwindling product pipelines and ever-increasing costs to deliver innovative treatments (Sternitzke, 2007;Vaudano, 2013;Woodstock, 2013). Not least because of the costs of up to USD 5.7 billion to develop an effective (disease-modifying) drug for Alzheimer's disease (Scott, 2014), the pharmaceutical industry has been cautious about large investments.…”

Translational Medicine

“…Such precompetitive consortia have sometimes been driven by government initiatives, such as with Europe's Innovative Medicines Initiative, which was founded in 2008 by the European Commission and the European Federation of Pharmaceutical Industries and Associations (Vaudano, 2013). Their effect has partly been to whet the appetite for greater collaboration, and there is an emerging new trend of precompetitive consortia that share information and knowledge-much of which was previously held proprietary-in the public domain.…”

Personalized medicine in hematology — A landmark from bench to bed

“…Currently there are several small molecular inhibitors in clinical practice. Table 4 summarizes the current small molecular inhibitors in clinical practice [92–96,130,131] .…”